Literatur
Age-Related Eye Disease Study Research Group (2001) The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol 132:668–681
Bird AC, Bressler NM, Bressler SB et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367–374
Klein R, Davis MD, Magli YL et al (1991) The Wisconsin age-related maculopathy grading system. Ophthalmology 98:1128–1134
Seddon JM, Sharma S, Adelman RA (2006) Evaluation of the clinical age-related maculopathy staging system. Ophthalmology 113:260–266
Ferris FL III, Wilkinson CP, Bird A et al (2013) Clinical classification of age-related macular degeneration. Ophthalmology 120:844–851
The Age-Related Eye Disease Study Research Group (1999) The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials 20:573–600
Downie LE, Keller PR (2014) Nutrition and age-related macular degeneration: research evidence in practice. Optom Vis Sci 91:821–831
Zampatti S, Ricci F, Cusumano A et al (2014) Review of nutrient actions on age-related macular degeneration. Nutr Res 34:95–105
SanGiovanni JP, Chew EY (2005) The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 24:87–138
Sperduto RD, Ferris FL, Kurinij N (1990) Do we have a nutritional treatment for age-related cataract or macular degeneration? Arch Ophthalmol 108:1403–1405
Newsome DA, Swartz M, Leone NC et al (1988) Oral zinc in macular degeneration. Arch Ophthalmol 106:192–198
Schutt F, Pauleikhoff D, Holz FG (2002) Vitamins and trace elements in age-related macular degeneration. Current recommendations, based on the results of the AREDS study. Ophthalmologe 99:301–303
Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119:1417–1436
Grossklaus R, Henning KJ (2009) Vitamins for the eyes? Risks and opportunities for physician and patient. Ophthalmologe 106:521–526
Lonn E, Bosch J, Yusuf S et al (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293:1338–1347
Miller ER, Pastor-Barriuso R, Dalal D et al (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37–46
AREDS2 Group (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309:2005–2015
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029–1035
Omenn GS, Goodman GE, Thornquist MD et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155
Ferris FL, Davis MD, Clemons TE et al (2005) A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 123:1570–1574
Chew EY, Clemons TE, Agrón E et al (2013) Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology 120:1604–1611
Chew EY, Clemons T, SanGiovanni JP et al (2012) The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 119:2282–2289
Aronow ME, Chew EY (2014) Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions. Curr Opin Ophthalmol 25:186–190
Evans JR, Lawrenson JG (2014) A review of the evidence for dietary interventions in preventing or slowing the progression of age-related macular degeneration. Ophthalmic Physiol Opt 34:390–396
Van Leeuwen R, Boekhoorn S, Vingerling JR et al (2005) Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 294:3101–3107
Redaktionskomitee
[“Financial disclosure“ nach Vorgabe der Association for Research in Vision and Ophthalmology (ARVO): Kategorie 1: Unterstützung von Forschungsprojekten und klinischen Studien, Kategorie 2: Beratung, Honorare, Reisekosten]
Dr. med. Arno P. Göbel
Kat. 1: Heidelberg Engineering, Optos, Zeiss
Kat. 2: Novartis
Priv.-Doz. Dr. med. Monika Fleckenstein
Kat. 1: Acucela, Alcon, Allergan, Bayer, Genentech, Heidelberg Engineering, Novartis, Optos, Zeiss
Kat. 2: Bayer, Heidelberg Engineering, Novartis
Prof. Dr. med. Bernd Bertram
ø
Prof. Dr. med. Daniel Pauleikhoff
Kat. 1: Alcon, Allergan, Bayer, Genentech, Heidelberg Engineering, Novartis
Kat. 2: Allergan, Alcon, Bayer, Genentech, Heidelberg Engineering, Novartis, Roche
Prof. Dr. med. Horst Helbig
Kat. 1: Acucela, Allergan, Bayer, Novartis
Kat. 2: Alcon, Alimera, Allergan, Bayer, Heidelberg, Novartis
Prof. Dr. med. Frank G. Holz
Kat. 1: Acucela, Alcon, Allergan, Bayer, Genentech, Heidelberg Engineering, Novartis, Optos, Zeiss
Kat. 2: Acucela, Allergan, Alcon, Bayer, Genentech, Heidelberg Engineering, Novartis, Roche
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Consortia
Additional information
Diese Stellungnahme erscheint ebenfalls in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, Georg Thieme Verlag, Stuttgart.
Rights and permissions
About this article
Cite this article
Deutsche Ophthalmologische Gesellschaft. Nahrungsergänzungsmittel bei altersabhängiger Makuladegeneration. Ophthalmologe 112, 35–40 (2015). https://doi.org/10.1007/s00347-014-3220-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-014-3220-z